


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DISCLAIMER IN PATENT UNDER 37 CFR 1.321(a)Name of Patentee
Regeneron Pharmaceuticals, Inc.Docket Number (Optional)
REGN-008CIPCONSPatent Number
10,888,601Date Patent Issued
January 12, 2021Title of Invention
USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERSI hereby disclaim the following complete claims in the above identified patent: 3, 4, 13, 14, 22, 29, 30The extent of my interest in said patent is (if assignee of record, state liber and page, or reel and frame, where assignment is recorded): Assignee of record (Reel/Frame: 050278/0613)

The fee for this disclaimer is set forth in 37 CFR 1.20(d).

- ☐ Patentee claims small entity status. See 37 CFR 1.27.
- ☐ Small entity status has already been established in this case, and is still proper.
- ☐ A check in the amount of the fee is enclosed.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge any fees which may be required or credit any overpayment to Deposit Account No. 50-0815.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.Signed at TARRYTOWN State of NEW YORK this 11TH day of JULY 20 22

Signature

50,437

Registration Number, if applicable

VP, Assoc Gen Counsel, Intellectual Property, Regeneron Pharmaceuticals, Inc.

914-847-1116

Typed or printed name of patentee/ attorney or agent of record

Telephone Number

777 Old Saw Mill River Road

Address

Tarrytown, NY 10591

City, State, Zip Code or Foreign Country as applicable

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.